Health Condition 1: N944- Primary dysmenorrhea
Conditions
Interventions
Intervention1: Transdermal Magnesium: An informed consent will be signed by all the participants. Transdermal magnesium will be given as spray applied to the abdomen and lower back with 3-5sprays with
Sponsors
Galgotias University
Eligibility
Inclusion criteria
Inclusion criteria: Participants must be females aged 18-30 with primary dysmenorrhea and a WALLID score above a specified threshold. They should be willing to provide informed consent, attend intervention sessions, and complete follow-up assessments. Participants must also be able to understand and communicate in the study language, follow instructions, and complete questionnaires. A negative patch test with no irritation or burning from transdermal magnesium application is required.
Exclusion criteria
Exclusion criteria: Participants will be excluded if they have a history of secondary dysmenorrhea (e.g., due to endometriosis or pelvic inflammatory disease), a WALLID score below a specified threshold, or are pregnant or planning to become pregnant during the study. Those using hormonal contraceptives or medications affecting the menstrual cycle or pain perception within a specified time frame are also excluded. Individuals with a history of chronic pelvic pain, psychiatric disorders, or current use of psychotropic medications are not eligible. Participation in other dysmenorrhea-related interventions or clinical trials during the study period is prohibited. Other exclusions include inability to comply with the protocol, medical conditions that pose safety risks, known allergies to magnesium or components of the transdermal formulation, and physical limitations preventing participation in pelvic floor exercises. Participants who experience itching or burning during the patch test will also be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main primary outcome to be assess will be menstrual pain on Wallid scale, functional activities of daily living with Barthel index scale and mental well-being by WHO-5 scale.Timepoint: Baseline (day 1) once a month during menstrual cycle for 6 months and once a month follow up for 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDevika Sunil
Galgotias University
Outcome results
None listed